Cystic Fibrosis News Digest — Issue 03

Fatih Ercan, Sevgi Pekcan, Semih Erden, et al.

Summary: This Turkish cross-sectional study compared alexithymia scores — measured by the validated Toronto Alexithymia Scale (TAS-20) — between adolescents aged 14–18 with cystic fibrosis and age-matched healthy controls. Patients with CF scored significantly higher on the TAS-20, indicating greater difficulty identifying and describing emotional states. A statistically significant negative correlation was observed between TAS-20 scores and FEV1, suggesting that more severe alexithymia tracks with worse pulmonary function.

Why it matters: Alexithymia — the reduced capacity to recognize and articulate one's own emotions — is associated in other chronic illness populations with poorer treatment adherence, worse quality of life, and suboptimal engagement with psychosocial support. If elevated alexithymia is genuinely more prevalent in CF adolescents and correlates with declining lung function, it could represent an underrecognized barrier to self-management, adherence to complex treatment regimens, and effective communication with care teams. The study raises a reasonable clinical question: are multidisciplinary CF teams adequately screening for emotional processing difficulties, especially in adolescents who are clinically deteriorating?

Expert perspective: The research question is legitimate and clinically relevant, and the use of a validated instrument (TAS-20) is appropriate. However, several limitations should temper interpretation. First, cross-sectional design prevents any causal inference: it cannot be determined whether alexithymia contributes to worse pulmonary outcomes, whether worsening illness fosters emotional blunting as a coping response, or whether both reflect a common underlying vulnerability. The negative correlation between TAS-20 scores and FEV1 is intriguing but is equally consistent with all three possibilities. Second, the sample is adolescent-only, limiting generalizability to younger children or adults with CF. Third, the abstract does not report the sample size — a notable gap in a rare disease population with a narrow age window, where small numbers could meaningfully inflate the risk of a Type I error. Fourth, the healthy control comparison does not account for the emotional burden of any serious chronic illness; a comparison with adolescents managing other chronic conditions would have strengthened the specificity of the finding to CF. Fifth, important confounders — including socioeconomic status, family functioning, mental health comorbidities, and access to psychosocial support — are not described in the available abstract. The authors' recommendation for integrated psychiatric support within multidisciplinary CF care is clinically sensible and consistent with existing CF foundation guidelines, but this recommendation predates the current study and does not depend solely on its findings. Overall, this is useful preliminary evidence that identifies alexithymia as worthy of systematic clinical attention in CF, but the findings are best treated as hypothesis-generating rather than practice-changing.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42631608/

---

MacKenzie L Wyatt, Karen S Raraigh, Anna V Faino, et al.

Summary: This meta-analysis of 25 published studies (606 children total) examined whether specific CFTR variants of varying clinical consequence (VVCCs) differ in their probability of causing diagnostic transition from CRMS/CFSPID to cystic fibrosis. Among the 268 children carrying one VVCC paired with one CF-causing variant, 28% ultimately converted to a CF diagnosis. Penetrance varied substantially by specific variant: some (5T;TG13, Q1476X, P5L) carried ≥50% conversion risk, while others (R117H;7T, D1270N, F1052V) carried considerably lower risk. Elevated sweat chloride was the most common clinical feature observed at the time of conversion.

Why it matters: CRMS/CFSPID represents a genuine clinical challenge born of the success of newborn screening — identifying infants who may or may not develop CF, generating significant family anxiety and uncertain clinical trajectories. Knowing that specific VVCCs confer meaningfully different conversion risks gives clinicians and genetic counselors a more granular, variant-level framework for counseling rather than treating all VVCCs as interchangeable. The findings also have direct policy relevance: decisions about which CFTR variants to include in newborn screening panels have downstream consequences for the volume and composition of the CRMS/CFSPID population, and variant-specific risk data can sharpen those inclusion criteria.

Expert perspective: This is a carefully framed meta-analysis addressing a real and underserved question, and its clinical usefulness is genuine — but several methodological limitations temper confidence in the specific numeric estimates. The fundamental constraint is the aggregate sample size: while 606 children is substantial for a rare condition, once the data are stratified by individual VVCC, most variant-specific estimates rest on very small denominators. Confidence intervals around the reported penetrance figures for individual variants are presumably wide, though the abstract does not present them explicitly — a notable omission. Readers should be cautious about treating point estimates such as "≥50% conversion" for 5T;TG13 or "low risk" for R117H;7T as definitive, as these numbers may shift materially with additional cases.

The meta-analytic approach introduces further complications. Pooling across 25 manuscripts spanning different countries, time periods, diagnostic criteria, and follow-up durations creates substantial heterogeneity. CRMS/CFSPID diagnostic thresholds differ between US and international settings, which could affect who is counted at baseline and who counts as "converted." Follow-up duration is a particularly important variable: a child classified as non-converted at age two might convert at age five, making shorter-follow-up studies systematically undercount true penetrance. Selection bias is also plausible, as published cohorts may overrepresent children with more symptomatic presentations or those followed at specialized CF centers with higher clinical vigilance. None of these limitations negate the work's value. The qualitative signal — that penetrance varies substantially across VVCCs — is almost certainly real even if the precise estimates are uncertain. The finding that elevated sweat chloride is the dominant conversion signal also reinforces the continued centrality of sweat testing in CRMS/CFSPID follow-up. Replication in prospective, standardized registries with harmonized follow-up protocols would meaningfully strengthen these variant-specific estimates.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42629235/

---

Marcus Svedberg, Christina Krantz, Henrik Imberg

Summary: This prospective multicentre observational study from two Swedish CF centres followed 46 children aged 6–17 years on elexacaftor/tezacaftor/ivacaftor (ETI) who reduced hypertonic saline inhalation and airway clearance techniques (ACTs) from twice to once daily over 12 months. The primary outcome, lung clearance index (LCI), showed a small non-significant improvement, while FEV₁% predicted remained essentially unchanged. Antibiotic use fell by 39%, and respiratory symptoms and airway microbiology were stable.

Why it matters: Airway clearance regimens impose a substantial daily burden on children and families, and the question of whether they can be safely reduced in the ETI era is clinically pressing and practically important. This study provides prospective — rather than retrospective or anecdotal — evidence that halving prescribed ACT and hypertonic saline frequency was not associated with measurable pulmonary deterioration over a 12-month horizon. The accompanying reduction in antibiotic use is notable, though its direction of causality is not straightforward to interpret. If this finding is confirmed in larger, longer, and ideally randomized studies, it could meaningfully reshape treatment guidelines and reduce daily treatment burden for thousands of children with CF.

Expert perspective: The study is prospectively designed and uses LCI — a sensitive measure of ventilation inhomogeneity — as its primary endpoint, which is an appropriate choice given that FEV₁ is often near-normal in well-controlled pediatric CF on ETI. The baseline LCI of 6.6 and FEV₁ of 97% predicted confirm that this is a relatively healthy, well-treated cohort, which is both a strength and a limitation, as ceiling effects may mask early subtle deterioration.

The most significant methodological concern is the absence of a control arm. Without a contemporaneous group continuing twice-daily therapy, it is impossible to determine whether stability reflects the safety of the reduction or simply the natural trajectory of ETI-treated children over 12 months. The sample size of 46 is modest, and the 95% confidence interval for the LCI change spans −0.67 to +0.03, meaning a clinically meaningful worsening cannot be ruled out — the study is underpowered to definitively exclude harm. A 12-month follow-up may not capture slower trajectories of structural lung disease progression that become apparent over years, particularly given that bronchiectasis can accrue insidiously even in the absence of symptomatic exacerbations.

The 39% reduction in antibiotic days is striking, but its interpretation is ambiguous: reduced ACT frequency might genuinely reduce antibiotic need, or clinicians and families may have been less inclined to treat minor symptoms aggressively in the context of an intentional protocol-guided reduction, introducing behavioral or ascertainment bias. The clinical bottom line is appropriately cautious: this is a promising, hypothesis-generating result. It should encourage — but not yet justify — broad clinical adoption of reduced ACT regimens outside of structured protocols. A randomized non-inferiority trial with longer follow-up, larger sample size, and imaging endpoints would be the necessary next step.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42632792/

---

Vincenzo G Menditto, Giovanni Pomponio, Nicole Caporelli, et al.

Summary: This systematic review and individual patient data (IPD) meta-analysis synthesized 18 studies examining whether CFTR modulator (CFTRm) therapy administered to pregnant women — either carriers or mothers with CF — can prevent or treat fetal meconium ileus (MI). Among 42 fetuses with antenatally diagnosed MI who were exposed to CFTRm, only 12% required surgical intervention. Compared with a historical control cohort, this represented a putative 59.5% absolute risk reduction in surgery. Importantly, none of nine asymptomatic fetuses exposed to CFTRm developed MI. Meta-regression identified earlier diagnosis (second trimester) and treatment duration of at least five weeks as factors associated with better outcomes.

Why it matters: Meconium ileus affects approximately 15–20% of newborns with CF and carries meaningful morbidity, including the need for major abdominal surgery, potential short-gut complications, and prolonged neonatal hospitalization. The possibility that maternal CFTR modulator therapy — primarily elexacaftor/tezacaftor/ivacaftor (ETI) in the cases reported — could reduce or prevent this complication represents a genuinely important clinical question as more women with CF or carriers reach reproductive age in the modulator era. The finding regarding asymptomatic fetuses, if validated, would have immediate implications for prenatal counseling and management, particularly as prenatal genotyping and fetal ultrasound anomaly detection become more routine.

Expert perspective: The authors are appropriately cautious, and the reader should be equally so. The evidence base here is constructed almost entirely from case reports and small observational series — the building blocks of hypothesis generation, not hypothesis confirmation. An IPD meta-analysis is a methodologically sophisticated tool, but pooling 18 small, heterogeneous, largely uncontrolled studies does not transform weak primary evidence into strong evidence.

The comparison with a historical cohort is the most precarious element. Historical controls differ from contemporary exposed patients in genotype distribution, prenatal diagnostic practices, gestational age at detection, access to specialized neonatal surgical care, and — crucially — the likelihood that cases treated with CFTRm in recent years are detected earlier and managed more intensively precisely because clinicians are aware of the potential intervention. This is a profound confounding-by-indication and ascertainment-bias problem that cannot be adequately adjusted away. The 42 fetuses with antenatally diagnosed MI represent an extremely small sample: the 95% CI for the proportion requiring surgery runs from 6% to 25%, and for the absolute risk reduction from 44% to 69% — ranges compatible with a range of clinically quite different realities. The meta-regression findings must be interpreted with maximum caution; fitting a regression model to 42 patients with multiple covariates is prone to overfitting, and the confidence intervals on key odds ratios span two to three orders of magnitude (e.g., OR 15.15, 95% CI 1.41–162.73), signaling high uncertainty rather than precision.

The mechanism by which a drug administered to a carrier mother could affect fetal gut function is not straightforward, and drug levels in fetal tissues, the degree of fetal CFTR modulation achieved, and fetal genotype are relevant variables that are inconsistently reported across the included studies. In summary, this paper provides the best available synthesis of a small and inherently limited literature, and the biological plausibility of benefit is real. The signal justifies prospective study. It does not justify routine clinical recommendations for CFTRm use in carrier mothers solely to prevent fetal MI outside of carefully designed trials or registries with informed consent and systematic follow-up. The authors acknowledge this honestly.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42632793/

---

Christina L Duncan, Megan von Isenburg, Angela Green, et al.

Summary: This multicenter cross-sectional study examined mental and behavioral health symptoms in 118 youth with cystic fibrosis (ages 7–17) on elexacaftor/tezacaftor/ivacaftor (ETI) and their caregivers across 11 U.S. CF centers. Clinically elevated depressive and anxiety symptoms were found in roughly one-quarter to one-third of both caregivers and youth. Sleep disturbance was flagged in nearly a third of youth, and caregiver mental health scores were meaningfully correlated with child mental health scores. The authors conclude that routine mental health screening remains warranted even in the ETI era, and that family-based approaches deserve consideration.

Why it matters: ETI has transformed the physical trajectory of CF, but the assumption that improved lung function automatically resolves psychosocial burden has not been consistently supported — and this study adds structured, multi-site data reinforcing that point. The caregiver–child correlation is particularly actionable: it suggests that screening only the patient, while ignoring the caregiver, may leave a significant source of risk unaddressed. For CF care teams and policymakers, this argues for maintaining — and possibly expanding — integrated mental health services rather than scaling them back in the wake of therapeutic success.

Expert perspective: The study is modest in scope but methodologically reasonable for a cross-sectional prevalence inquiry. The use of standardized, validated screening instruments across 11 centers strengthens comparability, though the authors do not report how centers were selected, raising questions about whether the sample skews toward academic or comprehensive care programs. With only 118 participants, confidence intervals are wide (e.g., childhood anxiety prevalence 95% CI: 18–44%), limiting precision and making subgroup conclusions tentative.

The cross-sectional design is the most important limitation. It cannot establish whether the observed mental health burden predates ETI, emerged independently of CF severity, or represents a residual effect already declining. Without a pre-ETI baseline or a comparator group not on ETI, it is impossible to determine whether rates are higher, lower, or unchanged relative to the pre-modulator era. The caregiver–child correlations (ρ = 0.20–0.52) span a wide range of effect sizes, and shared-method variance — caregivers completing proxy reports about the child — likely inflates some correlations, a limitation not discussed. The prevalence figures — approximately 23–29% for depression and 19–31% for anxiety — are broadly comparable to rates reported in youth with other chronic conditions and in the general adolescent population, particularly post-pandemic. Without a contemporaneous comparator, it is difficult to attribute these rates specifically to CF burden versus broader societal trends in youth mental health.

On the positive side, the inclusion of ADHD, externalizing behaviors, and sleep disturbance — affecting nearly 30–35% of youth — adds meaningful breadth beyond anxiety and depression alone and aligns with other CF research. The practical implication — that CF programs should continue routine mental health screening and consider family-based models — is reasonable and grounded in the data. This is useful incremental evidence that reinforces existing clinical guidance with contemporary, ETI-era data, which has real operational value for programs reassessing their psychosocial service models in a changed therapeutic landscape.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42621765/

---